Author Correction: The landscape of d16HER2 splice variant expression across HER2-positive cancers.

An amendment to this paper has been published and can be accessed via a link at the top of the paper.

RPSAP52 lncRNA is overexpressed in pituitary tumors and promotes cell proliferation by acting as miRNA sponge for HMGA proteins.

Long non-coding RNAs (lncRNAs) are emerging as fundamental players in cancer biology. Indeed, they are deregulated in several neoplasias and have been associated with cancer progression, tumor recurrence, and resistance to treatment, thus representing potential biomarkers for cancer diagnosis, prognosis, and therapy. In this study, we aimed to identify lncRNAs associated with pituitary tumorigenesis.

Class 1, 2, and 3 -Mutated Metastatic Colorectal Cancer: A Detailed Clinical, Pathologic, and Molecular Characterization.

Purpose: mutations are grouped in activating -independent signaling as monomers (class 1-V600E) or as dimers (class 2-codons 597/601), and -dependent with impaired kinase activity (class 3-codons 594/596). Although clinical, pathologic, and molecular features of -mutated metastatic colorectal cancer (mCRC) are well known, limited data are available from the two other classes.

Experimental Design: Data from 117 patients with (92 class 1, 12 class 2, and 13 class 3)-mutated mCRC were collected.

The landscape of d16HER2 splice variant expression across HER2-positive cancers.

The HER2 splice variant characterized by the deletion of exon 16 and denominated as d16HER2, is associated with HER2-positive breast cancer (BC) aggressiveness, stemness, and trastuzumab susceptibility and is considered to be a "flag" of HER2 dependence. However, with the exception of quantitative real-time PCR analysis, easily reproducible assays are still lacking to clinically detect and quantify the d16HER2 expression. Further, no data on d16HER2 expression and its potential role are available in HER2-positive gastrointestinal malignancies.

Prognostic impact of ATM mutations in patients with metastatic colorectal cancer.

Tumors bearing homologous recombination deficiency are extremely sensitive to DNA double strand breaks induced by several chemotherapeutic agents. ATM gene, encoding a protein involved in DNA damage response, is frequently mutated in colorectal cancer (CRC), but its potential role as predictive and prognostic biomarker has not been fully investigated. We carried out a multicenter effort aimed at defining the prognostic impact of ATM mutational status in metastatic CRC (mCRC) patients.